LABP

Landos Biopharma, Inc. [LABP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LABP Stock Summary

Top 10 Correlated ETFs

LABP


Top 10 Correlated Stocks

LABP


In the News

01:00 26 Mar 2023 LABP

3 Top Biotech Penny Stocks Under $3 To Watch Right Now

Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:02 26 Mar 2023 LABP

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

10:59 26 Mar 2023 LABP

Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript

Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript

09:57 26 Mar 2023 LABP

Should You Buy Landos Biopharma (LABP) Ahead of Earnings?

Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

07:00 26 Mar 2023 LABP

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

Phase 1 trial initiation expected before yearend with topline results in 1H 2022

07:00 26 Mar 2023 LABP

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced the publication of a peer-reviewed article titled “First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of the LANCL2 pathway in psoriasis” in Scientific Reports. The peer-reviewed publication demonstrates omilancor's therapeutic efficacy in animal models of psoriasis.

07:00 26 Mar 2023 LABP

Landos Biopharma to Participate in Two Upcoming Investor Conferences in September

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos will participate in two upcoming virtual investor conferences in September.

07:00 26 Mar 2023 LABP

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine

BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it has entered into a research collaboration with Peter Calabresi, M.D., Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University (JHU) School of Medicine. This research funded by the National Institutes of Health (NIH) will focus on further validating the NLRX1 immunometabolic pathway in Multiple Sclerosis (MS).

07:00 26 Mar 2023 LABP

Landos Biopharma to Participate in Upcoming Investor Events

BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August.

05:08 26 Mar 2023 LABP

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT.

LABP Financial details

Company Rating
Neutral
Market Cap
10.67M
Income
-65.42M
Revenue
0
Book val./share
1.09
Cash/share
1.19
Dividend
-
Dividend %
-
Employees
46
Optionable
No
Shortable
Yes
Earnings
22 Mar 2023
P/E
-0.2
Forward P/E
-
PEG
-0.03
P/S
-
P/B
0.24
P/C
0.22
P/FCF
-0.2
Quick Ratio
8.77
Current Ratio
9.04
Debt / Equity
0.12
LT Debt / Equity
-
-
-
EPS (TTM)
-1.63
EPS next Y
-
EPS next Q
-
EPS this Y
-0.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
290%
-
-
-
-
SMA20
-28.95%
SMA50
-42.55%
SMA100
-32.5%
Inst Own
39.11%
Inst Trans
-14.55%
ROA
-109%
ROE
-93%
ROC
-1.24%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
45.88M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
0.211-1.92
52W High
-
52W Low
-
RSI
39.8
Rel Volume
0.09
Avg Volume
446.69K
Volume
40.55K
Perf Week
3.52%
Perf Month
-28.78%
Perf Quarter
-59.23%
Perf Half Y
-66.46%
-
-
-
-
Beta
-1.12698
-
-
Volatility
0.01%, 0.05%
Prev Close
2.04%
Price
0.265
Change
5.08%

LABP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0000.46
Net income per share
-0.26-0.58-0.77-0.98
Operating cash flow per share
-0.3-0.43-0.59-0.69
Free cash flow per share
-0.3-0.43-0.59-0.7
Cash per share
0.022.160.722.32
Book value per share
0.04-1.11-1.381.95
Tangible book value per share
0.04-1.111.141.95
Share holders equity per share
0.04-1.11-1.381.95
Interest debt per share
00.0100.01
Market cap
277.24M277.24M469.96M187.98M
Enterprise value
276.88M267.43M467.54M179.68M
P/E ratio
-45.87-20.59-15.59-4.89
Price to sales ratio
00010.44
POCF ratio
-40.2-28.08-20.47-6.95
PFCF ratio
-39.95-27.64-20.31-6.84
P/B Ratio
277.24-10.84-8.72.46
PTB ratio
277.24-10.84-8.72.46
EV to sales
0009.98
Enterprise value over EBITDA
-46.46-20.48-15.58-4.75
EV to operating cash flow
-40.15-27.08-20.36-6.64
EV to free cash flow
-39.9-26.66-20.2-6.53
Earnings yield
-0.02-0.05-0.06-0.2
Free cash flow yield
-0.03-0.04-0.05-0.15
Debt to equity
1.8-2.97-0.210.22
Debt to assets
0.641.510.20.18
Net debt to EBITDA
0.060.750.080.22
Current ratio
1.3916.562.715.55
Interest coverage
-1.98K-43.720-94.21
Income quality
1.140.730.760.7
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000.85
Research and developement to revenue
0002.31
Intangibles to total assets
0000
Capex to operating cash flow
0.010.020.010.02
Capex to revenue
000-0.02
Capex to depreciation
-0.54-1.53-1.32-2.24
Stock based compensation to revenue
0000.23
Graham number
0.53.814.896.56
ROIC
-20.57-0.46-0.72-0.61
Return on tangible assets
-2.16-0.27-0.54-0.41
Graham Net
0.01-1.130.431.9
Working capital
696K47.08M18.85M75.54M
Tangible asset value
1000K-25.58M44.74M76.27M
Net current asset value
696K-25.95M18.58M75.54M
Invested capital
0000
Average receivables
01.05M5000
Average payables
01.87M5.33M10.76M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
-6.040.530.56-0.5
Capex per share
0-0.010-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
00000
Net income per share
-0.32-0.6-0.37-0.28-0.2
Operating cash flow per share
-0.3-0.36-0.41-0.45-0.19
Free cash flow per share
-0.3-0.36-0.41-0.45-0.19
Cash per share
2.572.71.831.381.19
Book value per share
2.352.271.541.281.09
Tangible book value per share
2.352.271.541.281.09
Share holders equity per share
2.352.271.541.281.09
Interest debt per share
00.01000
Market cap
583.45M161.47M59.38M29.3M26.17M
Enterprise value
565.55M153.16M48.11M10.06M-2.71M
P/E ratio
-11.57-2.01-1-0.65-0.83
Price to sales ratio
00000
POCF ratio
-49.26-13.39-3.6-1.63-3.46
PFCF ratio
-48.19-13.43-3.6-1.63-3.46
P/B Ratio
6.212.120.960.570.59
PTB ratio
6.212.120.960.570.59
EV to sales
00000
Enterprise value over EBITDA
-45.04-7.77-3.32-0.910.34
EV to operating cash flow
-47.75-12.7-2.92-0.560.36
EV to free cash flow
-46.71-12.74-2.91-0.560.36
Earnings yield
-0.02-0.12-0.25-0.39-0.3
Free cash flow yield
-0.02-0.07-0.28-0.61-0.29
Debt to equity
0.120.220.250.130.12
Debt to assets
0.110.180.20.110.11
Net debt to EBITDA
1.430.420.781.743.66
Current ratio
9.45.554.998.929.04
Interest coverage
0-63.74000
Income quality
0.940.61.111.590.96
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.020000
Capex to revenue
00000
Capex to depreciation
-5.50-0.0200
Stock based compensation to revenue
00000
Graham number
4.085.523.582.842.2
ROIC
-0.21-0.32-0.33-0.760.68
Return on tangible assets
-0.12-0.22-0.19-0.19-0.16
Graham Net
2.292.211.451.221.06
Working capital
93.22M75.54M61.85M51.53M44.01M
Tangible asset value
93.92M76.27M62.1M51.53M44.01M
Net current asset value
93.14M75.54M61.85M51.53M44.01M
Invested capital
00000
Average receivables
10000000
Average payables
10.4M11.51M11.36M7.26M3.96M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.13-0.26-0.24-0.22-0.18
Capex per share
-0.010000

LABP Frequently Asked Questions

What is Landos Biopharma, Inc. stock symbol ?

Landos Biopharma, Inc. is a US stock , located in Blacksburg of Va and trading under the symbol LABP

What is Landos Biopharma, Inc. stock quote today ?

Landos Biopharma, Inc. stock price is $0.265 today.

Is Landos Biopharma, Inc. stock public?

Yes, Landos Biopharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap